{"doi":"10.20944/preprints202409.2204.v1","title":"<em>miR-181a</em>: Regulatory Roles, Cancer-Associated Signaling Pathway Disruptions, and Therapeutic Potential","abstract":"Introduction: microRNA-181a (miR-181a) is a crucial post-transcriptional regulator of many mRNA transcripts and ncRNAs, influencing cell proliferation, cancer cell stemness, apoptosis, and immune responses. Its abnormal expression has been characterized in numerous cancers, making it a significant genomic vulnerability and biomarker in cancer research. Areas Covered: Here, we summarize miR-181a’s correlation with poor patient outcomes across numerous cancers, and the mechanisms governing miR-181a’s activity and processing. We comprehensively describe miR-181a’s involvement in multiple regulatory cancer signaling pathways, cellular processes, and the tumor microenvironment. We also discuss current therapeutic approaches to targeting miR-181a, highlighting their limitations and future potential. Expert Opinion: miR-181a is a clinically relevant pan-cancer biomarker with potential as a therapeutic target in cancer. Its regulatory control of tumorigenic signaling pathways and immune responses positions it as a promising candidate for more personalized treatments. The success of miR-181a as a target relies on the development of specific therapeutics platforms. Future research on miR-181a's role in the tumor microenvironment and the RNA binding proteins that regulate its stability will help uncover new techniques to targeting miR-181a. Further research into miR-181a serum levels in patients undergoing therapy will help to better stratify patients and enhance therapeutic success.","journal":"Preprints.org","year":2024,"id":504000,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9612,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1228857,"name":"Zoè Jackson","orcid":null,"position":1,"is_corresponding":false},{"id":465339,"name":"Jose A. Colina","orcid":"0000-0002-9567-8783","position":2,"is_corresponding":false},{"id":464188,"name":"Sreeja C. Sekhar","orcid":"0000-0002-9827-5349","position":3,"is_corresponding":false},{"id":464191,"name":"Analisa DiFeo","orcid":"0000-0001-8319-6763","position":4,"is_corresponding":false},{"id":827762,"name":"Grace McIntyre","orcid":"0000-0003-1034-9997","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:10:35.597333Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}